眼黒色腫の世界市場レポート 2024年

眼黒色腫の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には8.5%の年間複合成長率（CAGR）で126億1,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、継続的な公衆衛生への取り組み、遺伝子と分子プロファイリングにおける進行中の調査、高齢化に関連する世界の動向など、いくつかの要因に起因すると考えられます。予測期間中に予想される主要動向には、診断と治療計画における人工知能（AI）の統合、標的療法の出現、希少疾患治療薬開発への注力、患者中心の医薬品承認プロセス、画像診断技術の進歩、イノベーションが含まれます。治療法や画像技術の技術進歩。これらの動向は総合的に、予測期間における眼黒色腫の理解と管理における予測される成長と進歩に貢献します。

眼がん症例の予想増加は、今後数年間で眼黒色腫市場の拡大を促進する重要な要因になると見込まれています。眼がんとは、眼の構造内での細胞の異常かつ制御不能な増殖を指します。検出技術の強化、認識の向上、治療選択肢の進歩により、早期症例を効果的に管理するための専門的な治療法や介入に対する需要が高まっています。たとえば、米国がん協会の2023年 1月の報告書によると、眼と眼窩がんの症例は2023年に3,490件に増加し、2021年の3,320件から5.12%増加しました。

予想される高齢者人口の増加は、近い将来、眼黒色腫市場の拡大を促進すると予想されます。眼がんの一種である眼黒色腫は、高齢者の環境要因や遺伝的素因への長期にわたる曝露により、加齢とともに蔓延する傾向があります。高齢者の人口が拡大すると、眼黒色腫の影響を受けやすい潜在的な人の数が増加します。 2022年 10月に世界保健機関が報告したように、60歳以上の人口は2021年の10億人から2022年には14億人に急増し、2050年までに2倍の21億人に増加すると予測されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の眼黒色腫市場の促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の眼黒色腫の市場規模実績と成長、2018～2023年
• 世界の眼黒色腫市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界の眼黒色腫市場、部位別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• ブドウ膜
• 強膜
• 網膜
• 世界の眼黒色腫市場、診断別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• イメージング
• 生検
• 眼科検査
• 世界の眼黒色腫市場、治療別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 手術
• 放射線治療
• 標的療法
• 免疫療法
• その他
• 世界の眼黒色腫市場、エンドユーザー別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 病院とクリニック
• 学術機関

第7章 地域と国の分析

• 世界の眼黒色腫市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界の眼球黒色腫市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 眼黒色腫市場の競合情勢
• 眼黒色腫市場の企業プロファイル
  • Pfizer Inc.
  • Johnson &Johnson
  • F. Hoffmann-La Roche Ltd
  • Merck &Co. Inc
  • AbbVie Inc.

第31章 その他の大手と革新的な企業

• Bayer AG
• Novartis AG
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Sanofi SA
• GlaxoSmithKline PLC
• Eli Lilly and Company
• Amgen Inc.
• Koninklijke Philips NV
• Carl Zeiss AG
• Genentech Inc.
• Elekta Instrument AB
• Brainlab AG
• Optos Plc
• Castle Biosciences Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在性分析

第36章 付録

Eye melanoma is a form of cancer that develops in the melanocytes, the cells responsible for producing melanin within the eye. This cancer can manifest in different parts of the eye, including the uvea, iris, and choroid. Eye melanoma stands as the most common primary intraocular cancer in adults and may lead to vision issues, alterations in eye color, and other symptoms, depending on its location and size.

The primary types of eye melanoma are found in the uvea, sclera, and retina. The uvea constitutes the middle layer of the eye, encompassing the iris, ciliary body, and choroid, housing blood vessels that supply nutrients to the eye. Various forms of radiation therapy, such as plaque brachytherapy, proton beam therapy, and stereotactic radiosurgery, are employed to target and reduce the size of uveal melanomas. Diagnosis involves imaging, biopsy, and eye examinations, while treatments include surgery, radiation therapy, targeted therapy, immunotherapy, and other approaches. These treatments are typically administered by end users such as hospitals, clinics, and academic institutes.

The eye melanoma market research report is one of a series of new reports from The Business Research Company that provides eye melanoma market statistics, including eye melanoma industry global market size, regional shares, competitors with an eye melanoma market share, detailed eye melanoma market segments, market trends and opportunities, and any further data you may need to thrive in the eye melanoma industry. This eye melanoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The eye melanoma market size has grown strongly in recent years. It will grow from $8.29 billion in 2023 to $9.1 billion in 2024 at a compound annual growth rate (CAGR) of 9.8%. The growth observed in the historical period can be attributed to several factors, including increased awareness and early detection efforts, an aging population with prolonged sun exposure, a rise in the incidence of skin cancer, the development of targeted therapies, and the establishment of patient advocacy and support programs. These factors collectively contributed to the growth and improvement in the management of eye melanoma during the historic period.

The eye melanoma market size is expected to see strong growth in the next few years. It will grow to $12.61 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%. The anticipated growth in the forecast period can be attributed to several factors, including continued public health initiatives, ongoing research in genetic and molecular profiling, and global trends related to an aging population. Major trends expected in the forecast period encompass the integration of artificial intelligence (AI) in diagnostics and treatment planning, the emergence of targeted therapies, a focus on rare disease drug development, patient-centric drug approval processes, advancements in diagnostic imaging technologies, innovations in treatment modalities, and technological advancements in imaging techniques. These trends collectively contribute to the projected growth and advancements in the understanding and management of eye melanoma in the forecasted period.

The projected rise in eye cancer cases is poised to be a significant driver for the eye melanoma market's expansion in the coming years. Eye cancer denotes the abnormal and uncontrolled growth of cells within the eye's structures. Enhanced detection techniques, increased awareness, and advancements in treatment options have led to a heightened demand for specialized therapies and interventions to effectively manage early cases. For example, according to the American Cancer Society's January 2023 report, eye and orbital cancer cases increased to 3,490 in 2023, marking a 5.12% growth from 3,320 in 2021. Therefore, the surge in eye cancer cases is expected to fuel the growth of the eye melanoma market.

The anticipated growth in the geriatric population is set to boost the eye melanoma market's expansion in the foreseeable future. Eye melanoma, a form of eye cancer, tends to become more prevalent with age due to prolonged exposure to environmental factors and genetic predispositions among older individuals. The expanding population of older adults increases the potential number of individuals susceptible to eye melanoma. As reported by the World Health Organization in October 2022, the population aged 60 and above surged from 1 billion in 2021 to 1.4 billion in 2022, with projections to double to 2.1 billion by 2050. Hence, the growing geriatric population is expected to drive the growth of the eye melanoma market.

The expected obstruction to the growth of the eye melanoma market lies in the high costs associated with cancer treatment. The expenses linked to cancer treatment, including surgeries, radiation therapy, and chemotherapy, often lead to substantial out-of-pocket costs for patients. This financial burden may delay or prevent access to treatment, particularly for those with inadequate insurance coverage, limiting their ability to afford advanced therapies and affecting treatment outcomes. For instance, according to the American Cancer Society Cancer Action Network's December 2022 findings, survivors' expenses, including follow-up care costs, averaged $1,881 per survivor. Additionally, 51% of surveyed patients reported incurring medical debts due to cancer-related expenses. Therefore, the high cost of cancer treatment is expected to hinder the eye melanoma market's growth.

Companies at the forefront of the eye melanoma treatment sector are dedicated to pioneering innovative and specialized treatments, particularly immunotherapies and targeted therapies, aiming to elevate patient outcomes and improve their quality of life. These novel treatment modalities have recently made significant strides in the field of oncology. For example, in January 2022, Immunocore Ltd., a UK-based biopharmaceutical firm specializing in soluble T-cell receptor technology for biological drug development, obtained approval from the U.S. Food and Drug Administration (FDA) for Kimmtrak (tebentafusp-tabn). This groundbreaking therapy, the first of its kind for individuals with unresectable or metastatic uveal melanoma (mUM), operates as an immunotherapy targeting the gp100 protein found on the surface of uveal melanoma cells. By activating the patient's immune system through engineered T-cell receptors, Kimmtrak enables a precision-focused approach to eliminating melanoma, leveraging specialized immune cells for cancer treatment.

In November 2021, Pfizer Inc., a prominent US-based pharmaceutical and biotechnology corporation, successfully acquired Trillium Therapeutics for $2.26 billion. This strategic acquisition has expanded Trillium's portfolio, enriching it with biologics designed to enhance the innate immune systems' ability to identify and eradicate cancer cells. Trillium Therapeutics, a Canada-based clinical-stage immuno-oncology company, focuses on developing innovative cancer therapies, including those directed towards eye melanoma. Their lead molecules, TTI-622 and TTI-621, operate by inhibiting the signal-regulatory protein α (SIRPα)-CD47 axis, identified as a crucial immune checkpoint in hematological malignancies.

Major companies operating in the eye melanoma market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc, AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Koninklijke Philips N.V., Carl Zeiss AG, Genentech Inc., Elekta Instrument AB, Brainlab AG, Optos Plc , Castle Biosciences Inc., Heidelberg Engineering, Nektar Therapeutics, RaySearch Laboratories AB, Nidek Co. Ltd, IDEAYA Biosciences, Immunocore Limited , Topcon Healthcare, Oraya Therapeutics Inc., Delcath Systems Inc.

North America was the largest region in the eye melanoma market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eye melanoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the eye melanoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The eye melanoma market consists of revenues earned by entities by providing fine needle aspiration (FNA) techniques, blood testing, and genetic testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The eye melanoma market also includes sales of drugs and therapeutics such as chemotherapy, cryotherapy, and photodynamic therapy (PDT). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Eye Melanoma Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on eye melanoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for eye melanoma? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The eye melanoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Site: Uvea; Sclera; Retina
• 2) By Diagnosis: Imaging; Biopsy; Eye Exam
• 3) By Treatment: Surgery; Radiation Therapy; Targeted Therapy; Immunotherapy; Other Treatment
• 4) By End User: Hospitals And Clinics; Academic Institutes
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd; Merck & Co. Inc; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Eye Melanoma Market Characteristics

3. Eye Melanoma Market Trends And Strategies

4. Eye Melanoma Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Eye Melanoma Market Size and Growth

• 5.1. Global Eye Melanoma Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Eye Melanoma Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Eye Melanoma Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Eye Melanoma Market Segmentation

• 6.1. Global Eye Melanoma Market, Segmentation By Site, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Uvea
• Sclera
• Retina
• 6.2. Global Eye Melanoma Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Imaging
• Biopsy
• Eye Exam
• 6.3. Global Eye Melanoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Surgery
• Radiation Therapy
• Targeted Therapy
• Immunotherapy
• Other Treatment
• 6.4. Global Eye Melanoma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals And Clinics
• Academic Institutes

7. Eye Melanoma Market Regional And Country Analysis

• 7.1. Global Eye Melanoma Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Eye Melanoma Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Eye Melanoma Market

• 8.1. Asia-Pacific Eye Melanoma Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Eye Melanoma Market, Segmentation By Site, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Eye Melanoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Eye Melanoma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Eye Melanoma Market

• 9.1. China Eye Melanoma Market Overview
• 9.2. China Eye Melanoma Market, Segmentation By Site, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Eye Melanoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Eye Melanoma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Eye Melanoma Market

• 10.1. India Eye Melanoma Market, Segmentation By Site, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Eye Melanoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Eye Melanoma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Eye Melanoma Market

• 11.1. Japan Eye Melanoma Market Overview
• 11.2. Japan Eye Melanoma Market, Segmentation By Site, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Eye Melanoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Eye Melanoma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Eye Melanoma Market

• 12.1. Australia Eye Melanoma Market, Segmentation By Site, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Eye Melanoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Eye Melanoma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Eye Melanoma Market

• 13.1. Indonesia Eye Melanoma Market, Segmentation By Site, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Eye Melanoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Eye Melanoma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Eye Melanoma Market

• 14.1. South Korea Eye Melanoma Market Overview
• 14.2. South Korea Eye Melanoma Market, Segmentation By Site, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Eye Melanoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Eye Melanoma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Eye Melanoma Market

• 15.1. Western Europe Eye Melanoma Market Overview
• 15.2. Western Europe Eye Melanoma Market, Segmentation By Site, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Eye Melanoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Eye Melanoma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Eye Melanoma Market

• 16.1. UK Eye Melanoma Market, Segmentation By Site, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Eye Melanoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Eye Melanoma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Eye Melanoma Market

• 17.1. Germany Eye Melanoma Market, Segmentation By Site, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Eye Melanoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Eye Melanoma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Eye Melanoma Market

• 18.5. France Eye Melanoma Market, Segmentation By Site, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.6. France Eye Melanoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.7. France Eye Melanoma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Eye Melanoma Market

• 19.9. Italy Eye Melanoma Market, Segmentation By Site, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.10. Italy Eye Melanoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.11. Italy Eye Melanoma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Eye Melanoma Market

• 20.13. Spain Eye Melanoma Market, Segmentation By Site, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.14. Spain Eye Melanoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.15. Spain Eye Melanoma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Eye Melanoma Market

• 21.1. Eastern Europe Eye Melanoma Market Overview
• 21.2. Eastern Europe Eye Melanoma Market, Segmentation By Site, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Eye Melanoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Eye Melanoma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Eye Melanoma Market

• 22.1. Russia Eye Melanoma Market, Segmentation By Site, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Eye Melanoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Eye Melanoma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Eye Melanoma Market

• 23.1. North America Eye Melanoma Market Overview
• 23.2. North America Eye Melanoma Market, Segmentation By Site, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Eye Melanoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Eye Melanoma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Eye Melanoma Market

• 24.1. USA Eye Melanoma Market Overview
• 24.2. USA Eye Melanoma Market, Segmentation By Site, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Eye Melanoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Eye Melanoma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Eye Melanoma Market

• 25.1. Canada Eye Melanoma Market Overview
• 25.2. Canada Eye Melanoma Market, Segmentation By Site, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Eye Melanoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Eye Melanoma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Eye Melanoma Market

• 26.1. South America Eye Melanoma Market Overview
• 26.2. South America Eye Melanoma Market, Segmentation By Site, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Eye Melanoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Eye Melanoma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Eye Melanoma Market

• 27.1. Brazil Eye Melanoma Market, Segmentation By Site, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Eye Melanoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Eye Melanoma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Eye Melanoma Market

• 28.1. Middle East Eye Melanoma Market Overview
• 28.2. Middle East Eye Melanoma Market, Segmentation By Site, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Eye Melanoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Eye Melanoma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Eye Melanoma Market

• 29.1. Africa Eye Melanoma Market Overview
• 29.2. Africa Eye Melanoma Market, Segmentation By Site, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Eye Melanoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Eye Melanoma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Eye Melanoma Market Competitive Landscape And Company Profiles

• 30.1. Eye Melanoma Market Competitive Landscape
• 30.2. Eye Melanoma Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Johnson & Johnson
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. F. Hoffmann-La Roche Ltd
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Merck & Co. Inc
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. AbbVie Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Eye Melanoma Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Novartis AG
• 31.3. Bristol-Myers Squibb Company
• 31.4. AstraZeneca PLC
• 31.5. Sanofi S.A.
• 31.6. GlaxoSmithKline PLC
• 31.7. Eli Lilly and Company
• 31.8. Amgen Inc.
• 31.9. Koninklijke Philips N.V.
• 31.10. Carl Zeiss AG
• 31.11. Genentech Inc.
• 31.12. Elekta Instrument AB
• 31.13. Brainlab AG
• 31.14. Optos Plc
• 31.15. Castle Biosciences Inc.

32. Global Eye Melanoma Market Competitive Benchmarking

33. Global Eye Melanoma Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Eye Melanoma Market

35. Eye Melanoma Market Future Outlook and Potential Analysis

• 35.1 Eye Melanoma Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Eye Melanoma Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Eye Melanoma Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer